perfosfamide has been researched along with B16 Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Borch, RF; Gipp, JJ; Joswig, C; Liu, J; Marakovits, JT; Mulcahy, RT; Schmidt, JP | 1 |
| Aoki, S; Fukuno, Y; Hayashi, S; Kawashima, M; Nagata, M; Taniguchi, S; Tominaga, M; Tsuruta, N; Yatsunami, J | 1 |
2 other study(ies) available for perfosfamide and B16 Melanoma
| Article | Year |
|---|---|
Synthesis and evaluation of nitroheterocyclic phosphoramidates as hypoxia-selective alkylating agents.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Hypoxia; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Melanoma, Experimental; Mice; Organophosphorus Compounds; Oxygen; Tumor Cells, Cultured | 2000 |
Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cisplatin; Clarithromycin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Male; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Roxithromycin; Skin Neoplasms; Tumor Cells, Cultured; Vindesine | 1999 |